profit from every $100 of sales.
$0$100
Exelixis
$69.00-1.20% today
+62.9% in 1 year
1-year low $40.741-year high $72.75
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $21.51 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Exelixis sold, what it kept, and what it did with the cash.
Sales went from $1.61 billion in 2022 to $2.32 billion in 2025, with $783 million of profit last year.
SalesProfit
Exelixis handed back more cash to shareholders than it generated last year.
Buybacks $948M
Free cash flow 2025$844M
Bought back its own shares$948M
Paid as dividends–
Cash vs. debt$482M vs. $173M
Exelixis vs. similar companies
Exelixis grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Exelixis | 21.5× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Exelixis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 988 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | |
| 951 | 1,382 | 1,553 | 1,758 | 2,092 | 2,236 | |
| 110 | 287 | 201 | 171 | 690 | 893 | |
| 119 | 300 | 222 | 197 | 719 | 922 | |
| 112 | 231 | 182 | 208 | 521 | 783 | |
| 0.35 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | |
| 96.3% | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% | |
| 11.1% | 20.0% | 12.5% | 9.3% | 31.8% | 38.5% | |
| 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,137 | 2,616 | 3,071 | 2,942 | 2,948 | 2,844 |
| Cash | 319 | 647 | 501 | 263 | 217 | 482 |
| Total debt | – | – | 190 | 190 | 191 | 173 |
| Total liabilities | 258 | 406 | 583 | 678 | 703 | 683 |
| 1,879 | 2,211 | 2,488 | 2,264 | 2,244 | 2,161 | |
| 318 | 322 | 325 | 321 | 296 | 282 | |
| 4.6% | 10.2% | 5.9% | 5.5% | 22.4% | 30.2% | |
| 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 209 | 401 | 363 | 333 | 700 | 884 | |
| – | – | 138 | 163 | 66 | 40 | |
| – | – | 224 | 170 | 634 | 844 | |
| Dividends paid | – | – | – | – | – | – |
| – | 0 | 0 | 550 | 652 | 948 | |
| 105 | 120 | 108 | 106 | 94 | 113 |
Valuation
- 21.5×
- 20.8×
- 0.42
- 6.7×
- 7.3×
- 19.9×
- 17.9×
- 5.0%
- 4.6%
- 0.0%
Profitability
- 96.4%
- 38.5%
- 33.7%
- 42.0%
- 35.0%
- 16.1%
- 40.2%
- 32.1%
- 42.1%
- 25.2%
Growth
- +18.6%
- +51.4%
- +33.2%
- –
- −3.6%
Financial health
- -0.1×
- 0.09
- 6.5%
- –
- 3.26
- 3.19
- 0.92
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 3%of 946
Top 5%of 872
Top 35%of 563
Top 31%of 868
Top 21%of 986
What analysts expect
- Average price target
- $45.71
- Range
- $36.00 – $54.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.87 | 0.75 | +16.0% |
| Feb 10, 2026 | 0.94 | 0.77 | +22.1% |
| Nov 4, 2025 | 0.78 | 0.69 | +13.9% |
| Jul 28, 2025 | 0.75 | 0.65 | +15.4% |
| May 13, 2025 | 0.62 | 0.36 | +73.1% |
| Feb 11, 2025 | 0.55 | 0.51 | +7.8% |
| Oct 29, 2024 | 0.40 | 0.35 | +14.3% |
| Aug 6, 2024 | 0.77 | 0.30 | +156.7% |
News
Forget the FDA Delay: 3 Reasons Exelixis Is Still a BuyYahoo Finance · Oct 24, 2026Is Exelixis Stock Engineered To Make You Money?Yahoo Finance · Oct 7, 2026Exelixis zanzalintinib NDA review extended three months by FDASeeking Alpha · Sep 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
80Pass
Benjamin Graham
71Pass
Philip Fisher
100Pass
Peter Lynch
100Pass
Joel Greenblatt
61Pass
Charlie Munger
99Pass
Terry Smith
97Pass
Questions about Exelixis
Is Exelixis a good stock to buy?
A strong, very profitable business at a fair price. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Exelixis AI analysis
What does Exelixis do?
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. It is in Biotechnology, based in Alameda, CA, United States, with 1,077 employees.
Does Exelixis pay a dividend?
No. Exelixis does not pay a dividend at the moment; in 2025 it returned $948 million to shareholders by buying back its own shares.
Is Exelixis stock halal?
Yes. Exelixis passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Exelixis stock done over the past year?
Up 62.9% over the past twelve months, to $69.00. It traded between $40.74 and $72.75 and is 5.2% below its high.
Who are Exelixis's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Exelixis's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.